United Kingdom · Report · Written statement
UIN HCWS61
Lord O’Shaughnessy Review into Commercial Clinical Trials
Introduced
22 November 2023
Last action
22 November 2023 · Written statement
Status
Commons
Sponsors
—
Subjects
Discovery layer
Source updated
22 November 2023
Summary
The UK demonstrated its strength in clinical research during the pandemic through the rapid design and set up of studies. Over 2 million people participated in COVID-19 trials of treatments and vaccines across the UK.The collaboration that arose between r...
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
22 November 2023
Written statement
The UK demonstrated its strength in clinical research during the pandemic through the rapid design and set up of studies. Over 2 million people participated in COVID-19 trials of treatments and vaccines across the UK.The collaboration that arose between r...
Source: Commons
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-statements/detail/2023-11-22/HCWS61
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenstatements/statements/1672082
- uk · ws-1672082 · source updated 22 November 2023